This is a working overview of peptide backbone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Topiramate, marketed as Topamax among other names, is an oral medication primarily prescribed for the treatment of epilepsy and the prophylaxis of migraines. For epilepsy, this includes treatment for generalized or focal seizures. It has also been used off-label for alcohol dependence and essential tremor. Common side effects include tingling, feeling tired, loss of appetite, abdominal pain, weight loss, and cognitive dysfunction, such as trouble concentrating. Serious side effects may include suicidal ideation, increased ammonia levels resulting in encephalopathy, and kidney stones. Topiramate can cause birth defects, including cleft lip and palate. Risks and benefits should be carefully discussed with the full treatment team. Topiramate is considered "probably compatible" with lactation and is not contraindicated for breastfeeding, though monitoring of the infant for diarrhea or poor weight gain may be considered. Its mechanism of action is unclear. Topiramate was first synthesized in a search for an oral hypoglycemic agent; however, it received its initial approval as an anticonvulsant in 1996. It is available as a generic medication. In 2023, it was the 71st most commonly prescribed medication in the United States, with more than 9 million prescriptions.
== Clinical significance == AST is similar to alanine transaminase (ALT) in that both enzymes are associated with liver parenchymal cells. The difference is that ALT is found predominantly in the liver, with clinically negligible quantities found in the kidneys, heart, and skeletal muscle, while AST is found in the liver, heart (cardiac muscle), skeletal muscle, kidneys, brain, and red blood cells. As a result, ALT is a more specific indicator of liver inflammation than AST, as AST may be elevated also in diseases affecting other organs, such as myocardial infarction, acute pancreatitis, acute hemolytic anemia, severe burns, acute renal disease, musculoskeletal diseases, and trauma. The elevated AST level in hemorrhagic fever caused by crimean-congo hemorrhagic fever virus is associated with high mortality rate. AST was defined as a biochemical marker for the diagnosis of acute myocardial infarction in 1954. However, the use of AST for such a diagnosis is now redundant and has been superseded by the cardiac troponins. Laboratory tests should always be interpreted using the reference range from the laboratory that performed the test. Example reference ranges are shown below:
Heseltine was summoned by BPC to be told to sort out his firm's debts, but instead persuaded them to accept, instead of payment, an equity stake of at least 40% in a new, merged business. The portmanteau name "Haymarket" was suggested by Sir Geoffrey Crowther, chairman of BPC.
Hyperphosphorylation is believed to contribute to the development and progression of FTLD-tau, but evidence is inconclusive regarding the extent of its influence. There are significant differences in phosphorylation states across FTLD tauopathies, and the reasons for these differences are currently unknown. Pick bodies, for example, are not phosphorylated. Tau aggregation in FTLD-tau occurs not only through accumulation and altered phosphorylation but also through a disrupted balance between 3R and 4R isoforms.
==== "Stolen election" conspiracy theories ==== Following Trump's victory, some Harris supporters on X shared election denial conspiracy theories, claiming that millions of ballots were "left uncounted" and there being something "not right" with the election. Such posts falsely claiming Trump "stole" the election peaked at noon the day after at 94,000 posts per hour, with many receiving amplification and gaining over a million views each. According to Gordon Crovitz, the CEO of the media rating system NewsGuard, the phrase "Trump cheated" received 92,100 mentions on the platform from midnight until the Wednesday morning after. Besides the claims from Harris's supporters, some Trump supporters baselessly claimed the disparity between other years, the 2020 election, and a then-incomplete 2024 voting total indicated voter fraud in the 2020 election. One major "basis" these false claims were founded upon was a claim that Biden won 20 million more votes in his prior election bid than Harris had in hers, at the time. American journalist and conspiracy theorist Wayne Madsen commented on Threads: "I'm beginning to believe our election was massively hacked just like happened a few weeks ago in the Republic of Georgia." At the time these claims were disseminated, votes were still being counted in many states. An estimate around the time using the Associated Press vote percentage total found that 16.2 million votes across 20 states and D.C. had yet to be counted.
Sources: en.wikipedia.org
=== EC 1.21.3 With oxygen as acceptor === EC 1.21.3.1: isopenicillin-N synthase EC 1.21.3.2: columbamine oxidase EC 1.21.3.3: reticuline oxidase EC 1.21.3.4: sulochrin oxidase ((+)-bisdechlorogeodin-forming) EC 1.21.3.5: sulochrin oxidase ((-)-bisdechlorogeodin-forming) EC 1.21.3.6: aureusidin synthase EC 1.21.3.7: tetrahydrocannabinolic acid synthase EC 1.21.3.8: cannabidiolic acid synthase EC 1.21.3.9: now classified as EC 1.21.98.2, dichlorochromopyrrolate synthase
A serous membrane lines the pericardial cavity of the heart, and reflects back to cover the heart, much like an under-inflated balloon would form two layers surrounding a fist. Called the pericardium, this serous membrane is a two-layered sac that surrounds the entire heart except where blood vessels emerge on the heart's superior side; The pleura is the serous membrane that surrounds the lungs in the pleural cavity; The peritoneum is the serous membrane that surrounds several organs in the abdominopelvic cavity. The tunica vaginalis is the serous membrane, which surrounds the male gonad, the testis. The two layers of serous membranes are named parietal and visceral. Between the two layers is a thin fluid filled space. The fluid is produced by the serous membranes and stays between the two layers to reduce friction between the walls of the cavities and the internal organs when they move with respect to one another, such as when the lungs inflate or the heart beats. Such movement could otherwise lead to inflammation of the organs.
These studies have produced models of protein adhesive and other biopolymer deteriorations and the concurrent pore system development. The reduction in bodily repair capability during aging is important to studies of senescence and age-associated disease, and allows the determination of age in living animals. Forensic science can use this technique to estimate the age of a cadaver or an objet d'art to determine authenticity.
Between 1815 and 1824, the Rev William Buckland, the first Reader of Geology at the University of Oxford, collected more fossilized bones of Megalosaurus and became the first person to describe a non-avian dinosaur in a scientific journal. The second non-avian dinosaur genus to be identified, Iguanodon, was purportedly discovered in 1822 by Mary Ann Mantell, the wife of English geologist Gideon Mantell, though this is disputed and some historians say Gideon had acquired remains years earlier. Gideon Mantell recognized similarities between his fossils and the bones of modern iguanas and published his findings in 1825. The study of these "great fossil lizards" soon became of great interest to European and American scientists. Owen recognized that the remains that had been found so far, Iguanodon, Megalosaurus and Hylaeosaurus, shared distinctive features, and so decided to present them as a distinct taxonomic group. As clarified by British geologist and historian Hugh Torrens, Owen had given a presentation about fossil reptiles to the British Association for the Advancement of Science in 1841, but reports of the time show that Owen did not mention the word "dinosaur", nor recognize dinosaurs as a distinct group of reptiles in his address. He introduced the Dinosauria only in the revised text version of his talk published in April 1842. With the backing of Prince Albert, the husband of Queen Victoria, Owen established the Natural History Museum, London, to display the national collection of dinosaur fossils and other biological and geological exhibits.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.